[P02BB01, trichlorfon, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Metrifonate.]
[J01GA01, streptomycin, Streptomycin may increase the neuromuscular blocking activities of Cisatracurium.]
[M03AB01, succinylcholine, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Succinylcholine.]
[J01CA16, sulbenicillin, Sulbenicillin may increase the neuromuscular blocking activities of Cisatracurium.]
[S01AB04, sulfacetamide, Sulfacetamide may increase the neuromuscular blocking activities of Cisatracurium.]
[J01EC02, sulfadiazine, Sulfadiazine may increase the neuromuscular blocking activities of Cisatracurium.]
[J01ED07, sulfamerazine, Sulfamerazine may increase the neuromuscular blocking activities of Cisatracurium.]
[J01EC01, sulfamethoxazole, Sulfamethoxazole may increase the neuromuscular blocking activities of Cisatracurium.]
[J01ED05, sulfamethoxypyridazine, Sulfamethoxypyridazine may increase the neuromuscular blocking activities of Cisatracurium.]
[J01EB06, sulfanilamide, Sulfanilamide may increase the neuromuscular blocking activities of Cisatracurium.]
[S01AB02, sulfisoxazole, Sulfisoxazole may increase the neuromuscular blocking activities of Cisatracurium.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Sulpiride is combined with Cisatracurium.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Sulthiame.]
[N06DA01, tacrine, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Tacrine.]
[J01CA15, talampicillin, Talampicillin may increase the neuromuscular blocking activities of Cisatracurium.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Cisatracurium.]
[R03CC03, terbutaline, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Terbutaline.]
[S01HA03, tetracaine, Tetracaine may increase the neuromuscular blocking activities of Cisatracurium.]
[S03AA02, tetracycline, Tetracycline may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may increase the neuromuscular blocking activities of Cisatracurium.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Cisatracurium.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Apomorphine.]
[L04AX02, thalidomide, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[J01BA02, thiamphenicol, Thiamphenicol may increase the neuromuscular blocking activities of Cisatracurium.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Cisatracurium.]
[L01AC01, thiotepa, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Thiotepa.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Thiopental.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Thiothixene.]
[B02AB01, aprotinin, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Aprotinin.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Tiapride.]
[J01CA13, ticarcillin, Ticarcillin may increase the neuromuscular blocking activities of Cisatracurium.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Tilidine.]
[P01AB02, tinidazole, Tinidazole may increase the neuromuscular blocking activities of Cisatracurium.]
[S01AA12, tobramycin, Tobramycin may increase the neuromuscular blocking activities of Cisatracurium.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of CNS depression can be increased when Cisatracurium is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Trazodone.]
[S01BA05, triamcinolone, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Triamcinolone.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Triazolam.]
[C03AA06, trichlormethiazide, The serum concentration of Trichlormethiazide can be increased when it is combined with Cisatracurium.]
[A03AB12, mepenzolate, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[S01EB04, demecarium, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Demecarium.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Trifluoperazine.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Trifluperidol.]
[N05AA05, triflupromazine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[D07AC02, fluclorolone, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Fluclorolone.]
[N04AA01, trihexyphenidyl, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[R03BA07, mometasone, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Mometasone.]
[A03AA05, trimebutine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Alimemazine.]
[N03AC02, trimethadione, Trimethadione may increase the neuromuscular blocking activities of Cisatracurium.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Trimethaphan.]
[N06AA06, trimipramine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Trimipramine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Cisatracurium.]
[A03BB01, butylscopolamine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, Troleandomycin may increase the neuromuscular blocking activities of Cisatracurium.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Vilazodone.]
[S01FA06, tropicamide, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Tropicamide.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Cisatracurium.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Tubocurarine.]
[S01AA05, tyrothricin, Tyrothricin may increase the neuromuscular blocking activities of Cisatracurium.]
[A07AA12, fidaxomicin, Fidaxomicin may increase the neuromuscular blocking activities of Cisatracurium.]
[S01AA28, vancomycin, Vancomycin may increase the neuromuscular blocking activities of Cisatracurium.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Ezogabine.]
[C08DA01, verapamil, Verapamil may increase the neuromuscular blocking activities of Cisatracurium.]
[N06AX09, viloxazine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Viloxazine.]
[N01AX15, xenon, Xenon may increase the neuromuscular blocking activities of Cisatracurium.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Zuclopenthixol.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Levetiracetam.]
[J01MA13, trovafloxacin, Trovafloxacin may increase the neuromuscular blocking activities of Cisatracurium.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Ziprasidone.]
[G04BD07, tolterodine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[J01DH04, doripenem, Doripenem may increase the neuromuscular blocking activities of Cisatracurium.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Atracurium.]
[S01FA01, atropine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[H02AB11, prednylidene, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Prednylidene.]
[L04AX01, azathioprine, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Azathioprine.]
[J01CA09, azlocillin, Azlocillin may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DF01, aztreonam, Aztreonam may increase the neuromuscular blocking activities of Cisatracurium.]
[R02AB04, bacitracin, Bacitracin may increase the neuromuscular blocking activities of Cisatracurium.]
[M03BX01, baclofen, The therapeutic efficacy of Cisatracurium can be increased when used in combination with Baclofen.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Lorcaserin.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Cisatracurium.]
[A02AA05, magnesium silicate, The therapeutic efficacy of Cisatracurium can be increased when used in combination with Magnesium silicate.]
[H02AA01, aldosterone, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Aldosterone.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Barbital.]
[C01AA01, acetyldigitoxin, The risk or severity of Cardiac Arrhythmia can be increased when Cisatracurium is combined with Acetyldigitoxin.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Cisatracurium.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Rasagiline.]
[C08CA13, lercanidipine, Lercanidipine may increase the neuromuscular blocking activities of Cisatracurium.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Mosapride.]
[N06DA02, donepezil, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Cisatracurium.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Cisatracurium.]
[R06AC06, thonzylamine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, Diethyl ether may increase the neuromuscular blocking activities of Cisatracurium.]
[J04AK05, bedaquiline, Bedaquiline may increase the neuromuscular blocking activities of Cisatracurium.]
[C04AX11, bencyclane, Bencyclane may increase the neuromuscular blocking activities of Cisatracurium.]
[C03AA01, bendroflumethiazide, The serum concentration of Bendroflumethiazide can be increased when it is combined with Cisatracurium.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Pomalidomide.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Benperidol.]
[J01MA15, gemifloxacin, Gemifloxacin may increase the neuromuscular blocking activities of Cisatracurium.]
[A12CC09, magnesium orotate, Magnesium orotate may increase the neuromuscular blocking activities of Cisatracurium.]
[S01AE07, moxifloxacin, Moxifloxacin may increase the neuromuscular blocking activities of Cisatracurium.]
[A06AX06, tegaserod, The therapeutic efficacy of Tegaserod can be decreased when used in combination with Cisatracurium.]
[R02AD01, benzocaine, Benzocaine may increase the neuromuscular blocking activities of Cisatracurium.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Naratriptan.]
[L04AA18, everolimus, Everolimus may increase the neuromuscular blocking activities of Cisatracurium.]
[A12CC05, magnesium aspartate, Magnesium aspartate may increase the neuromuscular blocking activities of Cisatracurium.]
[N04AC01, benztropine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[P03AX06, benzyl alcohol, Benzyl alcohol may increase the neuromuscular blocking activities of Cisatracurium.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Levomilnacipran.]
[C08EA02, bepridil, Bepridil may increase the neuromuscular blocking activities of Cisatracurium.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Vortioxetine.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Eslicarbazepine.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Vigabatrin.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Tasimelteon.]
[A16AA06, betaine, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Betaine.]
[S03BA03, betamethasone, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Betamethasone.]
[J01XA04, dalbavancin, Dalbavancin may increase the neuromuscular blocking activities of Cisatracurium.]
[A03BA03, hyoscyamine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[J01XX11, tedizolid, Tedizolid may increase the neuromuscular blocking activities of Cisatracurium.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Alfaxalone.]
[D11AA01, glycopyrronium, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[J01XA05, oritavancin, Oritavancin may increase the neuromuscular blocking activities of Cisatracurium.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may increase the neuromuscular blocking activities of Cisatracurium.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Acepromazine.]
[V04CX03, methacholine, Cisatracurium may decrease effectiveness of Methacholine as a diagnostic agent.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Cisatracurium.]
[A06AH03, naloxegol, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Naloxegol.]
[N04AA02, biperiden, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Cisatracurium.]
[S03AA06, gentamicin, Gentamicin may increase the neuromuscular blocking activities of Cisatracurium.]
[N06AX11, mirtazapine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[A03AA09, difemerine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[A07DA06, eluxadoline, The risk or severity of constipation can be increased when Cisatracurium is combined with Eluxadoline.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Flibanserin.]
[A06AD03, magnesium peroxide, Magnesium peroxide may increase the neuromuscular blocking activities of Cisatracurium.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Cariprazine.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Acetazolamide.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Acetophenazine.]
[S02AA10, acetic acid, Acetic acid may increase the neuromuscular blocking activities of Cisatracurium.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Aprobarbital.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Brivaracetam.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Bromazepam.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, The therapeutic efficacy of Cisatracurium can be increased when used in combination with Magnesium Aluminum Silicate.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cisatracurium.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Amineptine.]
[C08CA01, amlodipine, Amlodipine may increase the neuromuscular blocking activities of Cisatracurium.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Aniracetam.]
[C03CA02, bumetanide, Bumetanide may decrease the neuromuscular blocking activities of Cisatracurium.]
[N01BB01, bupivacaine, Bupivacaine may increase the neuromuscular blocking activities of Cisatracurium.]
[N07BC01, buprenorphine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Cisatracurium.]
[N06DA03, rivastigmine, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Rivastigmine.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Butorphanol.]
[J01MA09, sparfloxacin, Sparfloxacin may increase the neuromuscular blocking activities of Cisatracurium.]
[S01GX07, azelastine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[J01CE04, azidocillin, Azidocillin may increase the neuromuscular blocking activities of Cisatracurium.]
[S01AA26, azithromycin, Azithromycin may increase the neuromuscular blocking activities of Cisatracurium.]
[J01CA06, bacampicillin, Bacampicillin may increase the neuromuscular blocking activities of Cisatracurium.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Cisatracurium.]
[R03CC12, bambuterol, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Bambuterol.]
[N02BF02, pregabalin, The therapeutic efficacy of Cisatracurium can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Beclamide.]
[S01HA02, benoxinate, Oxybuprocaine may increase the neuromuscular blocking activities of Cisatracurium.]
[J01XX08, linezolid, Linezolid may increase the neuromuscular blocking activities of Cisatracurium.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Safinamide.]
[J01MA23, delafloxacin, Delafloxacin may increase the neuromuscular blocking activities of Cisatracurium.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may increase the neuromuscular blocking activities of Cisatracurium.]
[N04AA11, bornaprine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Brotizolam.]
[R03BA02, budesonide, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Budesonide.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Butobarbital.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of Cardiac Arrhythmia can be increased when Cisatracurium is combined with Acetyldigoxin.]
[N01BX04, capsaicin, Capsaicin may increase the neuromuscular blocking activities of Cisatracurium.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Vinylbital.]
[N03AF01, carbamazepine, Carbamazepine may decrease the neuromuscular blocking activities of Cisatracurium.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Cisatracurium.]
[A03AA03, camylofine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[J01CA03, carbenicillin, Carbenicillin may increase the neuromuscular blocking activities of Cisatracurium.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Carbinoxamine.]
[C07AG02, carvedilol, Carvedilol may increase the neuromuscular blocking activities of Cisatracurium.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Cisatracurium.]
[J01DE01, cefepime, Cefepime may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DD10, cefetamet, Cefetamet may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DD09, cefodizime, Cefodizime may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DC11, ceforanide, Ceforanide may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DD13, cefpodoxime, Cefpodoxime may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DD14, ceftibuten, Ceftibuten may increase the neuromuscular blocking activities of Cisatracurium.]
[J01GB14, plazomicin, Plazomicin may increase the neuromuscular blocking activities of Cisatracurium.]
[N03AX17, stiripentol, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Stiripentol.]
[J01AA13, eravacycline, Eravacycline may increase the neuromuscular blocking activities of Cisatracurium.]
[J01AA14, sarecycline, Sarecycline may increase the neuromuscular blocking activities of Cisatracurium.]
[J01AA15, omadacycline, Omadacycline may increase the neuromuscular blocking activities of Cisatracurium.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Cisatracurium.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Carbromal.]
[N01BA04, chloroprocaine, Chloroprocaine may increase the neuromuscular blocking activities of Cisatracurium.]
[R06AA06, chlorphenoxamine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Cisatracurium.]
[R03BB08, revefenacin, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[A06AX05, prucalopride, The therapeutic efficacy of Prucalopride can be decreased when used in combination with Cisatracurium.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Cinitapride.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Esketamine.]
[J01FA09, clarithromycin, Clarithromycin may increase the neuromuscular blocking activities of Cisatracurium.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Brexanolone.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Clobazam is combined with Cisatracurium.]
[J01AA11, clomocycline, Clomocycline may increase the neuromuscular blocking activities of Cisatracurium.]
[H02AB14, cloprednol, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Cloprednol.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Cisatracurium.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Cloxazolam.]
[H02AB17, cortivazol, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Cortivazol.]
[J01DC04, cefaclor, Cefaclor may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DB05, cefadroxil, Cefadroxil may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DC03, cefamandole, Cefamandole may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DB07, cefatrizine, Cefatrizine may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DB04, cefazolin, Cefazolin may increase the neuromuscular blocking activities of Cisatracurium.]
[J01CF03, methicillin, Meticillin may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DC09, cefmetazole, Cefmetazole may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DC06, cefonicid, Cefonicid may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DD12, cefoperazone, Cefoperazone may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DD01, cefotaxime, Cefotaxime may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DC05, cefotetan, Cefotetan may increase the neuromuscular blocking activities of Cisatracurium.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Cyamemazine.]
[J01DC07, cefotiam, Cefotiam may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DC01, cefoxitin, Cefoxitin may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DD03, cefsulodin, Cefsulodin may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DD02, ceftazidime, Ceftazidime may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DD07, ceftizoxime, Ceftizoxime may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DD04, ceftriaxone, Ceftriaxone may increase the neuromuscular blocking activities of Cisatracurium.]
[S01AA27, cefuroxime, Cefuroxime may increase the neuromuscular blocking activities of Cisatracurium.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Cisatracurium.]
[J01XX12, lefamulin, Lefamulin may increase the neuromuscular blocking activities of Cisatracurium.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Yohimbine.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Cisatracurium.]
[J01XX09, daptomycin, Daptomycin may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DB01, cephalexin, Cephalexin may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DB02, cephaloridine, Cefaloridine may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DB03, cephalothin, Cefalotin may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DB08, cephapirin, Cefapirin may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DB09, cephradine, Cefradine may increase the neuromuscular blocking activities of Cisatracurium.]
[H02AB13, deflazacort, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Deflazacort.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Lasmiditan is combined with Cisatracurium.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cisatracurium.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Dezocine.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Lumateperone.]
[S01AE06, gatifloxacin, Gatifloxacin may increase the neuromuscular blocking activities of Cisatracurium.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Frovatriptan.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Dichloralphenazone.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Cisatracurium.]
[C08CA16, clevidipine, Clevidipine may increase the neuromuscular blocking activities of Cisatracurium.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Valpromide.]
[J01FA13, dirithromycin, Dirithromycin may increase the neuromuscular blocking activities of Cisatracurium.]
[S03AA08, chloramphenicol, Chloramphenicol may increase the neuromuscular blocking activities of Cisatracurium.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cisatracurium.]
[A03AA08, dihexyverine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[D07XB03, fluprednidene, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Fluprednidene.]
[G04BD09, trospium, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Chlormezanone.]
[R02AD04, dyclonine, Dyclonine may increase the neuromuscular blocking activities of Cisatracurium.]
[C08CA17, levamlodipine, Levamlodipine may increase the neuromuscular blocking activities of Cisatracurium.]
[N05CD14, remimazolam, The risk or severity of sedation can be increased when Cisatracurium is combined with Remimazolam.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Cisatracurium is combined with Oliceridine.]
[P01BA01, chloroquine, The therapeutic efficacy of Cisatracurium can be increased when used in combination with Chloroquine.]
[C03AA04, chlorothiazide, The serum concentration of Chlorothiazide can be increased when it is combined with Cisatracurium.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.]
[N05AF03, chlorprothixene, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[S01AA02, chlortetracycline, Chlortetracycline may increase the neuromuscular blocking activities of Cisatracurium.]
[C03BA04, chlorthalidone, The serum concentration of Chlorthalidone can be increased when it is combined with Cisatracurium.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Cisatracurium.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Etifoxine.]
[N06BX18, vinpocetine, Vinpocetine may increase the neuromuscular blocking activities of Cisatracurium.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Ethyl loflazepate.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Felbamate.]
[J01DD08, cefixime, Cefixime may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DD15, cefdinir, Cefdinir may increase the neuromuscular blocking activities of Cisatracurium.]
[J01MB07, flumequine, Flumequine may increase the neuromuscular blocking activities of Cisatracurium.]
[R03BA03, flunisolide, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Flunisolide.]
[N01AB05, trichloroethylene, Trichloroethylene may increase the neuromuscular blocking activities of Cisatracurium.]
[R02AB03, fusafungin, Fusafungine may increase the neuromuscular blocking activities of Cisatracurium.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Gabapentin.]
[N07CA02, cinnarizine, Cinnarizine may increase the neuromuscular blocking activities of Cisatracurium.]
[J01MB06, cinoxacin, Cinoxacin may increase the neuromuscular blocking activities of Cisatracurium.]
[S03AA07, ciprofloxacin, Ciprofloxacin may increase the neuromuscular blocking activities of Cisatracurium.]
[L01XA01, cisplatin, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Cisplatin.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Citalopram.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Cisatracurium.]
[J01FF01, clindamycin, The risk or severity of neuromuscular blockade can be increased when Clindamycin is combined with Cisatracurium.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when Cisatracurium is combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Cisatracurium.]
[J04BA01, clofazimine, Clofazimine may increase the neuromuscular blocking activities of Cisatracurium.]
[N01BB10, levobupivacaine, Levobupivacaine may increase the neuromuscular blocking activities of Cisatracurium.]
[N06AA04, clomipramine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Clomipramine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Cisatracurium.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Granisetron.]
[J01CF02, cloxacillin, Cloxacillin may increase the neuromuscular blocking activities of Cisatracurium.]
[N05AH02, clozapine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Clozapine.]
[J01GB12, arbekacin, Arbekacin may increase the neuromuscular blocking activities of Cisatracurium.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Halazepam.]
[S02DA02, cocaine, Cocaine may increase the neuromuscular blocking activities of Cisatracurium.]
[C02KB01, metyrosine, Cisatracurium may increase the sedative activities of Metyrosine.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Codeine.]
[J01CA18, hetacillin, Hetacillin may increase the neuromuscular blocking activities of Cisatracurium.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Hexafluronium.]
[A03AB10, hexocyclium, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[J01XX04, spectinomycin, Spectinomycin may increase the neuromuscular blocking activities of Cisatracurium.]
[S01FA05, homatropine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Homatropine.]
[A03BB06, homatropine methylbromide, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[J01XB01, colistin, Colistin may increase the neuromuscular blocking activities of Cisatracurium.]
[J01DE02, cefpirome, Cefpirome may increase the neuromuscular blocking activities of Cisatracurium.]
[N01AB07, desflurane, Desflurane may increase the neuromuscular blocking activities of Cisatracurium.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Ifenprodil.]
[J01FA15, telithromycin, Telithromycin may increase the neuromuscular blocking activities of Cisatracurium.]
[R03BA08, ciclesonide, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Ciclesonide.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Desloratadine.]
[H01AX01, pegvisomant, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Pegvisomant.]
[C01AA06, lanatoside C, The risk or severity of Cardiac Arrhythmia can be increased when Cisatracurium is combined with Lanatoside C.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Almotriptan.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Ketazolam.]
[C08CA09, lacidipine, Lacidipine may increase the neuromuscular blocking activities of Cisatracurium.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Cisatracurium.]
[N03AX09, lamotrigine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[S01BA03, cortisone, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Cortisone.]
[N07BC04, lofexidine, The therapeutic efficacy of Cisatracurium can be increased when used in combination with Lofexidine.]
[S01AE04, lomefloxacin, Lomefloxacin may increase the neuromuscular blocking activities of Cisatracurium.]
[R06AX13, loratadine, Cisatracurium may increase the anticholinergic activities of Loratadine.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Lormetazepam.]
[J01DC08, loracarbef, Loracarbef may increase the neuromuscular blocking activities of Cisatracurium.]
[A06AD01, magnesium carbonate, Magnesium carbonate may increase the neuromuscular blocking activities of Cisatracurium.]
[B05XA10, magnesium phosphate, The therapeutic efficacy of Cisatracurium can be increased when used in combination with Magnesium phosphate.]
[C08CA11, manidipine, Manidipine may increase the neuromuscular blocking activities of Cisatracurium.]
[A03AA04, mebeverine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[D10AF04, meclocycline, Meclocycline may increase the neuromuscular blocking activities of Cisatracurium.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Medifoxamine.]
[H02AB15, meprednisone, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Meprednisone.]
[J01DH02, meropenem, Meropenem may increase the neuromuscular blocking activities of Cisatracurium.]
[J01CA14, methampicillin, Metampicillin may increase the neuromuscular blocking activities of Cisatracurium.]
[N04AA03, methixene, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[C04AX01, cyclandelate, Cyclandelate may increase the neuromuscular blocking activities of Cisatracurium.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Cyclobarbital.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Melperone.]
[S01AA22, micronomicin, Micronomicin may increase the neuromuscular blocking activities of Cisatracurium.]
[C03AA07, cyclopenthiazide, The serum concentration of Cyclopenthiazide can be increased when it is combined with Cisatracurium.]
[J01FA03, midecamycin, Midecamycin may increase the neuromuscular blocking activities of Cisatracurium.]
[S01FA04, cyclopentolate, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Cyclopentolate.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Minaprine.]
[J04AB01, cycloserine, Cycloserine may increase the neuromuscular blocking activities of Cisatracurium.]
[S01XA18, cyclosporine, The therapeutic efficacy of Cisatracurium can be increased when used in combination with Cyclosporine.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Moclobemide.]
[R06AX02, cyproheptadine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[M03CA01, dantrolene, The therapeutic efficacy of Cisatracurium can be increased when used in combination with Dantrolene.]
[J04BA02, dapsone, Dapsone may increase the neuromuscular blocking activities of Cisatracurium.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Deanol.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Cisatracurium.]
[J01AA01, demeclocycline, Demeclocycline may increase the neuromuscular blocking activities of Cisatracurium.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Nordazepam.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Niaprazine.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Tiagabine.]
[S01AA13, fusidic acid, Fusidic acid may increase the neuromuscular blocking activities of Cisatracurium.]
[J01MB04, pipemidic acid, Pipemidic acid may increase the neuromuscular blocking activities of Cisatracurium.]
[N07XX04, sodium oxybate, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Sodium oxybate.]
[S02BA08, fluocinolone acetonide, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Fluocinolone acetonide.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Escitalopram.]
[G04BD08, solifenacin, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[R02AA02, dequalinium, Dequalinium may increase the neuromuscular blocking activities of Cisatracurium.]
[N06AA01, desipramine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Desipramine.]
[C01AA07, deslanoside, The risk or severity of Cardiac Arrhythmia can be increased when Cisatracurium is combined with Deslanoside.]
[D07XC02, desoximetasone, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Desoximetasone.]
[H02AA03, desoxycorticosterone, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Desoxycortone.]
[J01DH03, ertapenem, Ertapenem may increase the neuromuscular blocking activities of Cisatracurium.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Dexamethasone.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Oxiracetam.]
[N04AA08, dexetimide, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03AA01, oxyphencyclimine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Cisatracurium.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Paramethadione.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Paroxetine.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Diamorphine.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Diazepam.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Phenacemide.]
[J01CE05, phenethicillin, Pheneticillin may increase the neuromuscular blocking activities of Cisatracurium.]
[S01AA29, dibekacin, Dibekacin may increase the neuromuscular blocking activities of Cisatracurium.]
[R02AA19, phenol, Phenol may increase the neuromuscular blocking activities of Cisatracurium.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Phensuximide.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Dibenzepin.]
[S02DA04, dibucaine, Cinchocaine may increase the neuromuscular blocking activities of Cisatracurium.]
[J01CF01, dicloxacillin, Dicloxacillin may increase the neuromuscular blocking activities of Cisatracurium.]
[A03AA07, dicyclomine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[A03AX04, pinaverium, Pinaverium may increase the neuromuscular blocking activities of Cisatracurium.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Pipamperone.]
[A03AB14, pipenzolate, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01DC04, ixabepilone, Ixabepilone may increase the neuromuscular blocking activities of Cisatracurium.]
[C03CA03, piretanide, Piretanide may decrease the neuromuscular blocking activities of Cisatracurium.]
[P02CB02, diethylcarbamazine, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Diethylcarbamazine.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Diethylpropion.]
[C08CA03, isradipine, Isradipine may increase the neuromuscular blocking activities of Cisatracurium.]
[D07XC04, diflucortolone, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Difluocortolone.]
[A03AB11, poldine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[C01AA04, digitoxin, The risk or severity of Cardiac Arrhythmia can be increased when Cisatracurium is combined with Digitoxin.]
[C01AA05, digoxin, The risk or severity of Cardiac Arrhythmia can be increased when Cisatracurium is combined with Digoxin.]
[N02CA01, dihydroergotamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Cisatracurium.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Hydromorphone.]
[D04AB07, pramoxine, Pramocaine may increase the neuromuscular blocking activities of Cisatracurium.]
[C08DB01, diltiazem, Diltiazem may increase the neuromuscular blocking activities of Cisatracurium.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Dimenhydrinate.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Pridinol.]
[R06AB03, dimethindene, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Progabide.]
[J01CE03, propicillin, Propicillin may increase the neuromuscular blocking activities of Cisatracurium.]
[S01HA04, proparacaine, Proparacaine may increase the neuromuscular blocking activities of Cisatracurium.]
[R06AA02, diphenhydramine, Diphenhydramine may increase the neuromuscular blocking activities of Cisatracurium.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Quazepam.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Cisapride.]
[S01XA23, sirolimus, Sirolimus may increase the neuromuscular blocking activities of Cisatracurium.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Cisatracurium.]
[C01BA03, disopyramide, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N07AA03, distigmine, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Distigmine.]
[S02AA12, rifamycin SV, Rifamycin may increase the neuromuscular blocking activities of Cisatracurium.]
[J04AB05, rifapentine, Rifapentine may increase the neuromuscular blocking activities of Cisatracurium.]
[D06AX11, rifaximin, Rifaximin may increase the neuromuscular blocking activities of Cisatracurium.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Riluzole.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Levocetirizine.]
[N01BB09, ropivacaine, Ropivacaine may increase the neuromuscular blocking activities of Cisatracurium.]
[J01MB01, rosoxacin, Rosoxacin may increase the neuromuscular blocking activities of Cisatracurium.]
[S01BC05, ketorolac, The risk or severity of adverse effects can be increased when Ketorolac is combined with Cisatracurium.]
[N06AA16, dothiepin, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Dosulepin.]
[N06AA12, doxepin, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Cisatracurium.]
[J01AA02, doxycycline, Doxycycline may increase the neuromuscular blocking activities of Cisatracurium.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cisatracurium.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Sertraline.]
[N01AB08, sevoflurane, Sevoflurane may increase the neuromuscular blocking activities of Cisatracurium.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Cisatracurium.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Sibutramine.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Cisatracurium.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Cisatracurium.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Sumatriptan.]
[V04CX07, edrophonium, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Edrophonium.]
[H01AA01, corticotropin, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Corticotropin.]
[J01MA05, temafloxacin, Temafloxacin may increase the neuromuscular blocking activities of Cisatracurium.]
[J01CA17, temocillin, Temocillin may increase the neuromuscular blocking activities of Cisatracurium.]
[G04BD05, terodiline, Terodiline may increase the neuromuscular blocking activities of Cisatracurium.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Thiopropazate.]
[G04BD01, emepronium, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Tianeptine.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Tofisopam.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Toloxatone.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Cisatracurium.]
[C03CA04, torsemide, Torasemide may decrease the neuromuscular blocking activities of Cisatracurium.]
[J01AA12, tigecycline, Tigecycline may increase the neuromuscular blocking activities of Cisatracurium.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Loprazolam.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Triclofos.]
[A03AB08, tridihexethyl, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[H02CA01, trilostane, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Trilostane.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Trimethobenzamide.]
[N04AA12, tropatepine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Cisatracurium.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Urapidil.]
[J01MA04, enoxacin, Enoxacin may increase the neuromuscular blocking activities of Cisatracurium.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Veralipride.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Epinastine.]
[N06AX16, venlafaxine, The risk or severity of adverse effects can be increased when Venlafaxine is combined with Cisatracurium.]
[S01GA03, xylometazoline, Xylometazoline may increase the neuromuscular blocking activities of Cisatracurium.]
[C08CA12, mepirodipine, Barnidipine may increase the neuromuscular blocking activities of Cisatracurium.]
[N05CF02, zolpidem, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[N03AX15, zonisamide, Zonisamide may increase the neuromuscular blocking activities of Cisatracurium.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Zotepine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Guanfacine.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Moricizine.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Ergotamine.]
[S01AA17, erythromycin, Erythromycin may increase the neuromuscular blocking activities of Cisatracurium.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Estazolam.]
[J04AK02, ethambutol, Ethambutol may increase the neuromuscular blocking activities of Cisatracurium.]
[R03BA09, fluticasone furoate, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Fluticasone furoate.]
[R03BA05, fluticasone, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Fluticasone.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cisatracurium.]
[J04AD03, ethionamide, Ethionamide may increase the neuromuscular blocking activities of Cisatracurium.]
[N04AA05, profenamine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, Ethosuximide may increase the neuromuscular blocking activities of Cisatracurium.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Ethotoin.]
[M01AC06, meloxicam, Meloxicam may increase the neuromuscular blocking activities of Cisatracurium.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Ethylmorphine.]
[N01BB07, etidocaine, Etidocaine may increase the neuromuscular blocking activities of Cisatracurium.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Cisatracurium.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Sertindole.]
[A02BA04, nizatidine, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Nizatidine.]
[J01MA08, fleroxacin, Fleroxacin may increase the neuromuscular blocking activities of Cisatracurium.]
[R06AX12, terfenadine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Terfenadine.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Bupropion.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Fluvoxamine.]
[R01AX06, mupirocin, Mupirocin may increase the neuromuscular blocking activities of Cisatracurium.]
[C08CA02, felodipine, Felodipine may increase the neuromuscular blocking activities of Cisatracurium.]
[C08EA01, fendiline, Fendiline may increase the neuromuscular blocking activities of Cisatracurium.]
[N03AX26, fenfluramine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Fenfluramine.]
[R03CC04, fenoterol, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Fenoterol.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Fentanyl.]
[G04BD02, flavoxate, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[J01CF05, floxacillin, Flucloxacillin may increase the neuromuscular blocking activities of Cisatracurium.]
[H02AA02, fludrocortisone, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Fludrocortisone.]
[D07XB01, flumethasone, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Flumethasone.]
[N07CA03, flunarizine, Flunarizine may increase the neuromuscular blocking activities of Cisatracurium.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Flunitrazepam.]
[D07AC08, fluocinonide, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Fluocinonide.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Melitracen.]
[H02AB03, fluocortolone, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Fluocortolone.]
[V03AZ01, ethanol, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[S01CB05, fluorometholone, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Fluorometholone.]
[N06AB03, fluoxetine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AF01, flupenthixol, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Fluphenazine.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Flurazepam.]
[N05AG01, fluspirilene, Fluspirilene may increase the neuromuscular blocking activities of Cisatracurium.]
[S02AA17, fosfomycin, Fosfomycin may increase the neuromuscular blocking activities of Cisatracurium.]
[S01AA07, framycetin, Framycetin may increase the neuromuscular blocking activities of Cisatracurium.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Furazolidone.]
[C03CA01, furosemide, Furosemide may decrease the neuromuscular blocking activities of Cisatracurium.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Cisatracurium is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Amisulpride.]
[N06DA04, galantamine, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Galantamine.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Gallamine.]
[C08DA02, gallopamil, Gallopamil may increase the neuromuscular blocking activities of Cisatracurium.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Bifemelane.]
[J01XA03, telavancin, Telavancin may increase the neuromuscular blocking activities of Cisatracurium.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be increased when Cabergoline is combined with Cisatracurium.]
[N03AD03, methsuximide, Methsuximide may increase the neuromuscular blocking activities of Cisatracurium.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Alfentanil.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Dexmedetomidine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Glutethimide.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Cisatracurium.]
[R02AB30, gramicidin, Gramicidin D may increase the neuromuscular blocking activities of Cisatracurium.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Cisatracurium.]
[N01AB01, halothane, Halothane may increase the neuromuscular blocking activities of Cisatracurium.]
[N05AH04, quetiapine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Iprazochrome.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Allobarbital.]
[B05CB03, magnesium citrate, Magnesium citrate may increase the neuromuscular blocking activities of Cisatracurium.]
[A12CC03, magnesium gluconate, Magnesium gluconate may increase the neuromuscular blocking activities of Cisatracurium.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Cisatracurium.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Hexobarbital.]
[C08CA10, nilvadipine, Nilvadipine may increase the neuromuscular blocking activities of Cisatracurium.]
[M02AA26, nimesulide, Nimesulide may increase the neuromuscular blocking activities of Cisatracurium.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Cisatracurium can be increased when used in combination with Hydrochlorothiazide.]
[R05DA03, hydrocodone, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[S02BA01, hydrocortisone, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Hydrocortisone.]
[C03AA02, hydroflumethiazide, The serum concentration of Hydroflumethiazide can be increased when it is combined with Cisatracurium.]
[G04BD06, propiverine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Prothipendyl.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Cisatracurium.]
[J04AB04, rifabutin, Rifabutin may increase the neuromuscular blocking activities of Cisatracurium.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Cisatracurium.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Sufentanil.]
[N06AA02, imipramine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Imipramine.]
[J01XA02, teicoplanin, Teicoplanin may increase the neuromuscular blocking activities of Cisatracurium.]
[R01AD07, tixocortol, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Tixocortol.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Tizanidine.]
[C03BA11, indapamide, The serum concentration of Indapamide can be increased when it is combined with Cisatracurium.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Milnacipran.]
[A03AA30, piperidolate, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, Articaine may increase the neuromuscular blocking activities of Cisatracurium.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Cisatracurium.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Ramelteon.]
[R06AE01, buclizine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Alprenolol.]
[C03BA02, quinethazone, The serum concentration of Quinethazone can be increased when it is combined with Cisatracurium.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Iproniazid.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Isocarboxazid.]
[N01AB06, isoflurane, Isoflurane may increase the neuromuscular blocking activities of Cisatracurium.]
[S01EB07, isoflurophate, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Isoflurophate.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Cisatracurium.]
[J04AC01, isoniazid, Isoniazid may increase the neuromuscular blocking activities of Cisatracurium.]
[R03CB01, isoproterenol, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Isoprenaline.]
[J01FA07, josamycin, Josamycin may increase the neuromuscular blocking activities of Cisatracurium.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Cisatracurium.]
[S01AA24, kanamycin, Kanamycin may increase the neuromuscular blocking activities of Cisatracurium.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Ketanserin.]
[J02AB02, ketoconazole, The therapeutic efficacy of Cisatracurium can be increased when used in combination with Ketoconazole.]
[N05AH03, olanzapine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[N04BC09, rotigotine, Cisatracurium may increase the sedative activities of Rotigotine.]
[J01MB02, nalidixic acid, Nalidixic acid may increase the neuromuscular blocking activities of Cisatracurium.]
[N04BB01, amantadine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Amantadine.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Cisatracurium.]
[N07AA30, ambenonium, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Ambenonium.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Cisatracurium.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Lacosamide.]
[C03CC01, ethacrynic acid, The therapeutic efficacy of Cisatracurium can be increased when used in combination with Etacrynic acid.]
[J01CA11, amdinocillin, Amdinocillin may increase the neuromuscular blocking activities of Cisatracurium.]
[J01CA08, amdinocillin pivoxil, Pivmecillinam may increase the neuromuscular blocking activities of Cisatracurium.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Levodopa.]
[S02DA01, lidocaine, Lidocaine may increase the neuromuscular blocking activities of Cisatracurium.]
[C08EX01, lidoflazine, Lidoflazine may increase the neuromuscular blocking activities of Cisatracurium.]
[J01FF02, lincomycin, Lincomycin may increase the neuromuscular blocking activities of Cisatracurium.]
[S01AA21, amikacin, Amikacin may increase the neuromuscular blocking activities of Cisatracurium.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Lisuride.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Lofepramine.]
[A07DA03, loperamide, Loperamide may increase the neuromuscular blocking activities of Cisatracurium.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Cisatracurium.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Cisatracurium.]
[J01AA04, lymecycline, Lymecycline may increase the neuromuscular blocking activities of Cisatracurium.]
[L01EG01, temsirolimus, Temsirolimus may increase the neuromuscular blocking activities of Cisatracurium.]
[B05XA11, magnesium chloride, Magnesium chloride may increase the neuromuscular blocking activities of Cisatracurium.]
[G04BX01, magnesium hydroxide, Magnesium hydroxide may increase the neuromuscular blocking activities of Cisatracurium.]
[A12CC10, magnesium oxide, Magnesium oxide may increase the neuromuscular blocking activities of Cisatracurium.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Cisatracurium can be increased when used in combination with Magnesium sulfate.]
[N06AA21, maprotiline, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Mazindol.]
[C02BB01, mecamylamine, The therapeutic efficacy of Cisatracurium can be increased when used in combination with Mecamylamine.]
[L01AA05, mechlorethamine, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Mechlorethamine.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Meclizine.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Medazepam.]
[C01AA08, medigoxin, The risk or severity of Cardiac Arrhythmia can be increased when Cisatracurium is combined with Metildigoxin.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Cisatracurium.]
[P01BC02, mefloquine, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Mefloquine.]
[J01FG01, pristinamycin, Pristinamycin may increase the neuromuscular blocking activities of Cisatracurium.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Melatonin.]
[N06DX01, memantine, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Memantine.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Meperidine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Cisatracurium.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Methylphenobarbital.]
[N01BB03, mepivacaine, Mepivacaine may increase the neuromuscular blocking activities of Cisatracurium.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Cisatracurium.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Meptazinol.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Paliperidone.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Dolasetron.]
[J01AA05, methacycline, Metacycline may increase the neuromuscular blocking activities of Cisatracurium.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Cisatracurium.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Metamfetamine.]
[A03AB07, methantheline, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Methaqualone.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Cisatracurium.]
[J01XX05, methenamine, Methenamine may increase the neuromuscular blocking activities of Cisatracurium.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Metergoline.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Cisatracurium.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Cisatracurium.]
[N02BG08, ziconotide, Ziconotide may increase the neuromuscular blocking activities of Cisatracurium.]
[N05AA02, methotrimeprazine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02BG09, methoxyflurane, Methoxyflurane may increase the neuromuscular blocking activities of Cisatracurium.]
[C03AA08, methyclothiazide, The serum concentration of Methyclothiazide can be increased when it is combined with Cisatracurium.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Cisatracurium.]
[V04CG05, methylene blue, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Methylene blue.]
[H02AB04, methylprednisolone, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Methylprednisolone.]
[D07AC14, methylprednisolone aceponate, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Methylprednisolone aceponate.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Cisatracurium.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Methyprylon.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Cisatracurium.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Cisatracurium.]
[C03BA08, metolazone, The serum concentration of Metolazone can be increased when it is combined with Cisatracurium.]
[P01AB01, metronidazole, Metronidazole may increase the neuromuscular blocking activities of Cisatracurium.]
[J01CA10, mezlocillin, Mezlocillin may increase the neuromuscular blocking activities of Cisatracurium.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Mianserin.]
[S02AA13, miconazole, The therapeutic efficacy of Cisatracurium can be increased when used in combination with Miconazole.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Midazolam.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Cisatracurium.]
[J01AA08, minocycline, Minocycline may increase the neuromuscular blocking activities of Cisatracurium.]
[J01FA11, miocamycin, Miocamycin may increase the neuromuscular blocking activities of Cisatracurium.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Molindone.]
[C01BD01, amiodarone, Amiodarone may increase the neuromuscular blocking activities of Cisatracurium.]
[N06AA09, amitriptyline, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Morphine.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Cisatracurium.]
[J01DD06, moxalactam, Latamoxef may increase the neuromuscular blocking activities of Cisatracurium.]
[L04AA06, mycophenolic acid, Mycophenolic acid may increase the neuromuscular blocking activities of Cisatracurium.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Vecuronium.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Amobarbital.]
[N06AA17, amoxapine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.]
[N03AB05, fosphenytoin, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Fosphenytoin.]
[J01CA04, amoxicillin, Amoxicillin may increase the neuromuscular blocking activities of Cisatracurium.]
[N04BC04, ropinirole, Cisatracurium may increase the sedative activities of Ropinirole.]
[J01CF06, nafcillin, Nafcillin may increase the neuromuscular blocking activities of Cisatracurium.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Nalbuphine.]
[N07BB04, naltrexone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Naltrexone.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Duloxetine.]
[S01AA10, natamycin, Natamycin may increase the neuromuscular blocking activities of Cisatracurium.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Cisatracurium.]
[S03AA01, neomycin, Neomycin may increase the neuromuscular blocking activities of Cisatracurium.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Remifentanil.]
[S01EB06, neostigmine, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Neostigmine.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Iloperidone.]
[J02AA01, amphotericin B, Amphotericin B may increase the neuromuscular blocking activities of Cisatracurium.]
[S01AA19, ampicillin, Ampicillin may increase the neuromuscular blocking activities of Cisatracurium.]
[S01AA23, netilmicin, Netilmicin may increase the neuromuscular blocking activities of Cisatracurium.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Desvenlafaxine.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Nialamide.]
[C08CA04, nicardipine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.]
[C08CA05, nifedipine, Nifedipine may increase the neuromuscular blocking activities of Cisatracurium.]
[C08CA06, nimodipine, Nimodipine may increase the neuromuscular blocking activities of Cisatracurium.]
[C08CA07, nisoldipine, Nisoldipine may increase the neuromuscular blocking activities of Cisatracurium.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Nitrazepam.]
[C08CA08, nitrendipine, Nitrendipine may increase the neuromuscular blocking activities of Cisatracurium.]
[J01XE01, nitrofurantoin, Nitrofurantoin may increase the neuromuscular blocking activities of Cisatracurium.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Zaleplon.]
[N04BC05, pramipexole, Cisatracurium may increase the sedative activities of Pramipexole.]
[N01AX13, nitrous oxide, Nitrous oxide may increase the neuromuscular blocking activities of Cisatracurium.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Nomifensine.]
[S01AE02, norfloxacin, Norfloxacin may increase the neuromuscular blocking activities of Cisatracurium.]
[N06AA10, nortriptyline, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.]
[G02CA02, nylidrin, Nylidrin may increase the neuromuscular blocking activities of Cisatracurium.]
[S02AA16, ofloxacin, Ofloxacin may increase the neuromuscular blocking activities of Cisatracurium.]
[J01FA05, oleandomycin, Oleandomycin may increase the neuromuscular blocking activities of Cisatracurium.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Opium.]
[P01AB03, ornidazole, The therapeutic efficacy of Cisatracurium can be increased when used in combination with Ornidazole.]
[C01AC01, ouabain, The risk or severity of Cardiac Arrhythmia can be increased when Cisatracurium is combined with Ouabain.]
[J01CF04, oxacillin, Oxacillin may increase the neuromuscular blocking activities of Cisatracurium.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Oxazepam.]
[J01MB05, oxolinic acid, Oxolinic acid may increase the neuromuscular blocking activities of Cisatracurium.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Oxycodone.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Oxypertine.]
[A03AB03, oxyphenonium, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[S01AA04, oxytetracycline, Oxytetracycline may increase the neuromuscular blocking activities of Cisatracurium.]
[J04AA01, aminosalicylic acid, Aminosalicylic acid may increase the neuromuscular blocking activities of Cisatracurium.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Cisatracurium.]
[M03AC01, pancuronium, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[J04AB30, capreomycin, Capreomycin may increase the neuromuscular blocking activities of Cisatracurium.]
[N05CC05, paraldehyde, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[H02AB05, paramethasone, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Paramethasone.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Pargyline.]
[A07AA06, paromomycin, Paromomycin may increase the neuromuscular blocking activities of Cisatracurium.]
[J01MA03, pefloxacin, Pefloxacin may increase the neuromuscular blocking activities of Cisatracurium.]
[G04BD11, fesoterodine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Penbutolol.]
[N05AG03, penfluridol, Penfluridol may increase the neuromuscular blocking activities of Cisatracurium.]
[S01AA14, penicillin G, Benzylpenicillin may increase the neuromuscular blocking activities of Cisatracurium.]
[J01CE09, penicillin G procaine, Procaine benzylpenicillin may increase the neuromuscular blocking activities of Cisatracurium.]
[J01CE02, penicillin V, Phenoxymethylpenicillin may increase the neuromuscular blocking activities of Cisatracurium.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Pentazocine.]
[N05CA01, pentobarbital, The risk or severity of adverse effects can be increased when Pentobarbital is combined with Cisatracurium.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Pergolide.]
[C08EX02, perhexiline, Perhexiline may increase the neuromuscular blocking activities of Cisatracurium.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Perphenazine.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Phenazocine.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Phenelzine.]
[N03AA02, phenobarbital, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Phenobarbital.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Cisatracurium.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Phenoperidine.]
[N03AB02, phenytoin, Phenytoin may decrease the neuromuscular blocking activities of Cisatracurium.]
[S01AE08, besifloxacin, Besifloxacin may increase the neuromuscular blocking activities of Cisatracurium.]
[S01AE05, levofloxacin, Levofloxacin may increase the neuromuscular blocking activities of Cisatracurium.]
[V03AB19, physostigmine, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Physostigmine.]
[C08CX01, mibefradil, Mibefradil may increase the neuromuscular blocking activities of Cisatracurium.]
[N05AG02, pimozide, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Pimozide.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Pindolol.]
[J01CA12, piperacillin, Piperacillin may increase the neuromuscular blocking activities of Cisatracurium.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Pipotiazine.]
[A02BX03, pirenzepine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Piritramide.]
[J01DD16, cefditoren, Cefditoren may increase the neuromuscular blocking activities of Cisatracurium.]
[J01MA11, grepafloxacin, Grepafloxacin may increase the neuromuscular blocking activities of Cisatracurium.]
[J01CA02, pivampicillin, Pivampicillin may increase the neuromuscular blocking activities of Cisatracurium.]
[N02CX01, pizotyline, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Proxibarbal.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Cisatracurium.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Alosetron.]
[S03AA03, polymyxin B, Polymyxin B may increase the neuromuscular blocking activities of Cisatracurium.]
[C03AA05, polythiazide, The serum concentration of Polythiazide can be increased when it is combined with Cisatracurium.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Prazepam.]
[S03BA02, prednisolone, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Prednisolone.]
[H02AB07, prednisone, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Prednisone.]
[C01DX02, prenylamine, Prenylamine may increase the neuromuscular blocking activities of Cisatracurium.]
[N01BB04, prilocaine, Prilocaine may increase the neuromuscular blocking activities of Cisatracurium.]
[N03AA03, primidone, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Primidone.]
[C01BA02, procainamide, Procainamide may increase the neuromuscular blocking activities of Cisatracurium.]
[S01HA05, procaine, Procaine may increase the neuromuscular blocking activities of Cisatracurium.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Procarbazine.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cisatracurium.]
[N04AA04, procyclidine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[N05AA03, promazine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Promazine.]
[R06AD02, promethazine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Propanidid.]
[A03AB05, propantheline, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Periciazine.]
[N05CM06, propiomazine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Propofol.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Dextropropoxyphene.]
[C01AB01, proscillaridin, The risk or severity of Cardiac Arrhythmia can be increased when Cisatracurium is combined with Proscillaridin.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Rizatriptan.]
[J04AD01, prothionamide, Protionamide may increase the neuromuscular blocking activities of Cisatracurium.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Cisatracurium.]
[N05AX12, aripiprazole, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.]
[A03AB15, diphemanil, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Cisatracurium.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Pyrantel.]
[J04AK01, pyrazinamide, Pyrazinamide may increase the neuromuscular blocking activities of Cisatracurium.]
[N07AA02, pyridostigmine, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Pyridostigmine.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Mepyramine.]
[C01BA01, quinidine, Quinidine may increase the neuromuscular blocking activities of Cisatracurium.]
[P01BC01, quinine, The therapeutic efficacy of Cisatracurium can be increased when used in combination with Quinine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Cisatracurium.]
[J04AB02, rifampin, Rifampicin may increase the neuromuscular blocking activities of Cisatracurium.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Oxitriptan.]
[J01AA09, rolitetracycline, Rolitetracycline may increase the neuromuscular blocking activities of Cisatracurium.]
[J01FA06, roxithromycin, Roxithromycin may increase the neuromuscular blocking activities of Cisatracurium.]
[S01FA02, scopolamine, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Cisatracurium.]
[V04CK01, secretin, The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Cisatracurium.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Selegiline.]
[D06BA01, silver sulfadiazine, Silver sulfadiazine may increase the neuromuscular blocking activities of Cisatracurium.]
[J01GB08, sisomicin, Sisomicin may increase the neuromuscular blocking activities of Cisatracurium.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Cisatracurium.]
[J01FA02, spiramycin, Spiramycin may increase the neuromuscular blocking activities of Cisatracurium.]
[C03DA01, spironolactone, Spironolactone may increase the neuromuscular blocking activities of Cisatracurium.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Chloral hydrate.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Cisatracurium.]
[D07AB02, hydrocortisone butyrate, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Hydrocortisone butyrate.]
[R03BB01, ipratropium bromide, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
